News Article | December 8, 2016
LISHUI, China, Dec. 8, 2016 /PRNewswire/ -- Tantech Holdings Ltd. (TANH) (Nasdaq: TANH) ("Tantech" or the "Company") announced today that it has successfully developed the new generation of infrared bamboo charcoal bedding articles, which feature excellent absorption, infrared and self-warming properties. These capabilities have been verified by the China National Supervision and Test Center for Eco-Product Quality, China National Supervision and Test Center for Infrared Product Quality, and Shanghai Research Institute of Chemical Industry Testing Center. The new generation of infrared bamboo charcoal bedding articles includes bamboo charcoal fiber bedclothes, health-care mattress and pillows. According to TANH engineers, the bamboo charcoal is made out of carefully-selected high quality natural Moso bamboo, or tortoise-shell bamboo, and carbonized at a temperate of 1,100 degrees centigrade. Compared to the predecessors, the new products have a more extensive micro porous structure and a higher specific surface area. By releasing abundant highly active anion, they can effectively absorb the smell of human body and eliminate sweat odor, helping revitalize and moisture skin. Meanwhile, the far infrared rays emitted by the bamboo charcoal can store energy and warm up human body to make sleep more comfortable. TANH Chairman Zhengyu Wang said the company has got rewarded for its vigorous research and development efforts. In addition to the upgraded bamboo charcoal products, the company has recently had three of its new energy vehicle models approved by the Ministry of Industry and Information for future launches. With the established postdoctoral workstation and researcher center, in the future the company will ramp up research and development on carbon materials, super electronic double layer capacitor carbon, batteries and new energy vehicles. The recent achievements will help the company lift sales, improve revenue and expand market share. As a leading bamboo charcoal manufacturer, TANH's products have long been welcomed by consumers. The company's "Dr. Charcoal" series, has launched more than 100 bamboo charcoal products that have capabilities of eliminating odor and purifying air. The "Dr. Charcoal" series, which enjoys wide recognition in China, has reached consumers in overseas markets including the United States, Japan, Korea and Europe. Established in 2001 and headquartered in Lishui City, Zhejiang Province, China, Tantech Holdings Ltd. ("Tantech" or the "Company"), together with its subsidiaries, develops and manufactures bamboo-based charcoal products, including a variety of branded consumer products and electric double-layer capacitor ("EDLC") carbon products for industrial energy applications. The Company is in the process of acquiring 100% interest in Suzhou E Motors Co., Ltd., a specialty electric vehicles and power batteries manufacturer based in Zhangjiagang City, Jiangsu Province, and aims to transform itself from a bamboo-based charcoal products producer to a vertically integrated company along the EDLC Carbon - power battery - specialty new energy vehicle value chain. For more information about Tantech, please visit: http://www.tantech.cn/en/index.asp. This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulations, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by this cautionary statement and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. For more information, please contact: To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tantech-develops-high-value-added-products-with-great-absorption-capacity-300375170.html
News Article | November 18, 2016
A1QA Company has successfully completed ISO/IEC 27001:2013 recertification, thus replacing a similar certificate of the year 2005. Preparing for the certification procedure, A1QA experts conducted a comprehensive analysis of the internalsecurity management system, corporate methodologies, risks identification and assessment controls. After that, the independent compliance audit of the Information Security Management System of A1QA was performed. The independent audit was run by the professional certificate organization. The experts evaluated A1QA infrastructure, hardware and software assets, as well as internal workflows. As a result, the Company’s activities were found adherent to international standards related to the protection of confidential data when providing software testing services and quality assurance consultancy services. "Mature Information Security Management System is based on comprehensive assessment of risks in development, monitoring and improvement of information security based on business requirements and regulatory frameworks. A1QA services compliance with ISO/IEC 27001:2013 requirementsis of great importance for our Security Testing Center of Excellence and for A1QA in general. The Certificate guarantees our customers and partners that we take responsible approach when dealing with confidential and sensitive data. In future, we are committed to do our best to make our customers feel confident and safe when partnering with A1QA," commented Anna Andreeva, Head of the Security Testing Center of Excellence. About A1QA For more than 12 years A1QA has been performing testing and quality assurance of software products of any complexity. Today, the company employs 400+ engineers with software testing experience in telecom, banks and finance, e-commerce and other domains. A1QA specialists have successfully delivered 1,400 solutions for such clients as adidas, airG, Kaspersky Lab, Acronis, Telekom Austria Group. Read about other A1QA news on the website Austin, TX, November 18, 2016 --( PR.com )-- ISO 27001 specifies requirements for establishing, implementing and improving the documented Information Security Management System to confirm company's ability to protect its data resources.Preparing for the certification procedure, A1QA experts conducted a comprehensive analysis of the internalsecurity management system, corporate methodologies, risks identification and assessment controls. After that, the independent compliance audit of the Information Security Management System of A1QA was performed.The independent audit was run by the professional certificate organization. The experts evaluated A1QA infrastructure, hardware and software assets, as well as internal workflows. As a result, the Company’s activities were found adherent to international standards related to the protection of confidential data when providing software testing services and quality assurance consultancy services."Mature Information Security Management System is based on comprehensive assessment of risks in development, monitoring and improvement of information security based on business requirements and regulatory frameworks. A1QA services compliance with ISO/IEC 27001:2013 requirementsis of great importance for our Security Testing Center of Excellence and for A1QA in general. The Certificate guarantees our customers and partners that we take responsible approach when dealing with confidential and sensitive data. In future, we are committed to do our best to make our customers feel confident and safe when partnering with A1QA," commented Anna Andreeva, Head of the Security Testing Center of Excellence.About A1QAFor more than 12 years A1QA has been performing testing and quality assurance of software products of any complexity. Today, the company employs 400+ engineers with software testing experience in telecom, banks and finance, e-commerce and other domains. A1QA specialists have successfully delivered 1,400 solutions for such clients as adidas, airG, Kaspersky Lab, Acronis, Telekom Austria Group.Read about other A1QA news on the website www.a1qa.com Click here to view the list of recent Press Releases from A1QA Software Testing Company
News Article | March 17, 2016
Forget mosquito bites. Volunteers let researchers inject them with the dengue virus in the name of science - and an experimental vaccine protected them. Next up, scientists plan to use this same strategy against dengue's cousin, the Zika virus. It's called a human challenge, a little-known but increasing type of research where healthy people agree to be deliberately infected in the quest for new or improved vaccines against a variety of health threats, from flu to malaria. Wednesday's dengue study offered more evidence that what sounds bizarre not only can be done safely, it can offer important clues for how well a shot might work. "What we're trying to do is accelerate vaccine research," said senior author Dr. Anna Durbin of Johns Hopkins University's school of public health. It may be the best way "to know if you have a stinker before you try to test it in thousands or tens of thousands of people." The dengue candidate proved highly promising, researchers reported in the journal Science Translational Medicine. Dengue fever may have slipped from the headlines as the related Zika virus sweeps through Latin America, but every year mosquito-borne dengue causes devastating outbreaks throughout the tropics and subtropics. While most people survive dengue with few or even no symptoms, more than 2 million a year suffer serious illness and about 25,000 die. Creating a vaccine has been tough. It must work against four separate strains of dengue, and a shot that's only partially protective might backfire. That's because people who survive one type of dengue can suffer worse symptoms if they're later infected with another strain. Enter an experimental vaccine created at the National Institutes of Health, made from four live but weakened dengue strains. Initial studies had suggested the shots were safe and promising. But, "we really wanted to have an early clue that it was go to work," especially against the hard-to-prevent dengue serotype 2, said Dr. Stephen Whitehead of NIH's National Institute of Allergy and Infectious Diseases, who led the vaccine development. Researchers at Hopkins and the University of Vermont gave 41 healthy people who'd never been exposed to dengue either a single dose of the vaccine or a dummy shot. Six months later, those volunteers were challenged - injected with a weakened version of that dengue-2 strain. The results were striking: All 21 people who'd gotten the real vaccine were completely protected - while all 20 who'd gotten a placebo had dengue virus in their bloodstream and either a mild rash or a temporary drop in white blood cell count, researchers reported Wednesday. This kind of study mimics "the closest that it can be to what may happen in natural infection," said Dr. Nikos Vasilakis, a virologist at the University of Texas Medical Branch in Galveston, who wasn't involved in the new work but calls the NIH shot "one of the better vaccine candidates." Based in part on the findings, the Butantan Institute in Brazil last month began recruiting 17,000 people, ages 2 to 59, for the final testing needed to prove how well the NIH vaccine works against dengue in real-world conditions, when it is spread by mosquitoes. A competing vaccine, made by Sanofi Pasteur, recently was approved by Brazilian regulators for ages 9 to 45. What about Zika, the dengue relative that's been linked to babies born with unusually small heads? Already, researchers are planning similar challenge studies that could start even before there's a vaccine candidate, Durbin said. "We see a Zika challenge model as really beneficial for not only vaccine development but also to learn more about Zika itself," she explained. "We know very little about Zika right now," including how long it stays in blood and other parts of the body. Key to these challenge studies: Scientists must modify a virus strain in the laboratory so that it doesn't make volunteers openly ill but still is strong enough to spark a mild infection, what Whitehead called "that perfect in-between." Plus, that mimics what happens with both dengue and Zika, where most people who become infected never report symptoms. Before deliberately infecting someone, "you have to know that it's a completely controllable situation, that it's a mild and controlled infection," said Dr. Beth Kirkpatrick, who directs the University of Vermont Vaccine Testing Center that tested the dengue model.
Qiao J.,China Agricultural University |
Rao Z.,Testing Center |
Dong B.,China Agricultural University |
Cao Y.,China Agricultural University
Applied Biochemistry and Biotechnology | Year: 2010
The 1014 nucleotides long gene-encoding β-mannanase from Bacillus subtilis strain MA139 was cloned using PCR. To obtain high expression levels in Pichia pastoris, the β-mannanase gene was optimized according to the codon usage bias of P. pastoris and fused downstream of GAP promoter. The reconstituted plasmid pGAP-mann was transformed into P. pastoris X-33 strain to constitutively express β-mannanase. When cultured at 28∈°C for 3 days protein yields up to 2.7 mg/mL was obtained with the enzyme activity of up to 230 U/mL. In comparison, wild-type gene product yielded 1.9 mg/mL and 170 U/mL, respectively indicating that the protein yield and enzyme activity were significantly improved by codon modification. After purification, the enzyme properties were characterized. The optimal activity was at pH 6.0 and 50∈°C. In the pH range of 3.0 to 9.0, β-mannanase showed above 60% of its peak activity. Among the numerous ions tested copper significantly inhibited the enzyme activity. These results suggested that codon-optimized β-mannanase expressed in P. pastoris could potentially be used as an additive in the feed for monogastric animals. © 2009 Humana Press.
Jia J.,Testing Center |
Liang C.,Testing Center |
Cao J.,Testing Center |
Li Z.,Testing Center
Journal of Microbiological Methods | Year: 2013
An algorithm of Probabilistic Neural Network (PNN) for bacterial identification based on the probability matrix of API 20E system as a case study is reported. The PNN shows the correct identification of all the taxa belonging to the training and test sets and possesses merits over the conventional methods. © 2013 Elsevier B.V.
Zhou M.,Soochow University of China |
Qin S.,Soochow University of China |
Chu Y.,Soochow University of China |
Wang F.,Testing Center |
And 2 more authors.
International Journal of Clinical and Experimental Pathology | Year: 2014
Matrix metalloproteinase (MMP)-2 and MMP-9, two important members of the matrix metalloproteinase family, have been shown critical contributions in intra-tumor angiogenesis and invasion of tumor progression, and they might also play important roles in the angiogenesis as well as the pannus formation of rheumatoid arthritis (RA). In the present study, we used the immunohistochemistry, the immunofluorescence staining and the con-focal scanning methods to characterize the immunolocalization of MMP-2 and MMP-9 in RA synovium tissues. Our results showed that both MMP-2 and MMP-9 immunostaining could be found in synoviocytes and vascular endothelial cells. Moreover, our con-focal scanning also showed that MMP-2 could be found in infiltrating CD14+ monocytes and CD68+ macrophages, and MMP-9 could be found in infiltrating CD68+ macrophages in RA synovium tissues, while weak or negative staining of these two MMPs could be found in infiltrating CD20+B cells and CD3+T cells in RA synovium. Thus, our finding suggests that both MMP-2 and MMP-9 expressed by synoviocytes as well as certain infiltrating immune cells role importantly in the angiogenesis in RA progression.
Chen L.,Soochow University of China |
Lu Y.,Soochow University of China |
Chu Y.,Soochow University of China |
Xie J.,Soochow University of China |
And 2 more authors.
Acta Histochemica | Year: 2013
Angiogenesis, as well as pannus formation within the joint, plays an important role in the erosion of articular cartilage and bone in the pathological process of rheumatoid arthritis (RA). Tissue factor (TF), an essential initiator of the extrinsic pathway of blood coagulation, is also involved in the angiogenesis and the pannus formation of RA progression. In the present study, we used immunofluorescence and confocal scanning methods to characterize TF immunolocalization in RA synovium. We showed that positive staining of TF could be immunolocalized in synoviocytes, CD19+ B cells and CD68+ macrophages, whereas weak or negative staining of tissue factor could be found in CD34+ endothelial cells of neo-vessels, CD3+ T cells and CD14+ monocytes in RA synovium tissues. Our study demonstrates a detailed local expression of TF in the rheumatoid synovium, and supports the notion that TF, expressed not only by the synoviocytes themselves, but also the infiltrating CD19+ B cells and CD68+ macrophages, is involved in the pannus invasion in the progression of rheumatoid arthritis. © 2013 Elsevier GmbH.
Chu Y.,Soochow University of China |
Wang F.,Testing Center |
Zhou M.,Soochow University of China |
Chen L.,Soochow University of China |
Lu Y.,Soochow University of China
Acta Histochemica | Year: 2014
Rheumatoid arthritis (RA) is a chronic and systematic autoimmune inflammatory disease. Recently, a novel T cell subset, follicular helper CD4 T cell (Tfh cells) was found in relation to the pathogenesis and progression of RA, and increased numbers of circulating Tfh cells were found in RA patients. However, there is little evidence regarding the localization of Tfh cells in synovium tissues from RA patients, owing to the lack of an available method to characterize their localization in tissue. The aim of our present study was to characterize the Tfh cells in rheumatoid synovium tissues from RA patients by using immunohistochemistry and triple-fluorescence immunostaining methods. Our results showed that specific staining of CD4, CXCR5 and ICOS could be found on infiltrating immune cells in rheumatoid synovium tissues. The use of triple-fluorescence immunostaining and confocal laser scanning showed immunolocalization of CD4+CXCR5+ICOS+T cells (Tfh cells) in the rheumatoid synovium tissues, whereas these signals were absent in osteoarthritis (OA) synovium and in normal synovium tissues. Thus the data from our present preliminary study support the notion that CD4+CXCR5+ICOS+Tfh cells could be found in rheumatoid synovium tissues from RA patients, indicating the possibility that this T cell subset in synovium tissues may have important roles in the pathogenesis and progression of RA. © 2013 Elsevier GmbH.
News Article | February 15, 2017
Net-Translators, an industry-leading provider of medical device localization, software localization, website translation, technical documentation translation and multilingual testing services, announced today that it will present a joint webinar with QualiTest, the world’s second largest pure-play software testing and quality assurance company, on Thursday, February 23, 2017 at 11:00 am EST. Entitled “How to get localization and testing for medical devices done right”, the webinar targets companies involved in software development and localization of medical devices. Additional information and registration are available by clicking here. Shy Avni, CEO and co-founder of Net-Translators, said, “Following the recent announcement of our partnership with QualiTest, we’re excited to share how our combined solutions enable medical device companies to produce the highest quality software and products.” He adds: “When developing medical and healthcare systems, even the smallest mistakes could have devastating results. Our combined testing and localization solutions not only shorten the development and time-to-market cycles, but also ensure that the devices are 100% functional and safe.” Hosted by Nausheen Sayed, VP of US-UK Knowledge and Innovation at QualiTest and David Sommer, Director of Strategic Operations at Net-Translators, the 60-minute webinar focuses on: Although geared toward the medical device industry, this webinar is a great fit for anyone involved in the localization and translation or software development process. About Net-Translators (http://www.net-translators.com) Net-Translators is a leading provider of translation, localization, and multilingual testing services in more than 60 languages. For over a decade, Net-Translators has helped global companies prepare their products and services for worldwide deployment. The company’s service portfolio includes the language services needed to localize and test software, medical devices, and websites including localization of user interfaces, online help, technical and marketing materials. Net-Translators’ one-of-a-kind Multilingual Testing Center offers translation quality assessments, professional testing staff and a dedicated localization testing environment for products of all kinds. Net-Translators is certified ISO 9001:2008, ISO 13485:2003 and EN 15038:2006, and specializes in translation of materials for compliance to international regulations. About QualiTest (http://www.qualitestgroup.com) QualiTest is the world’s second largest pure play outsourced software testing and quality assurance specialist with offices in the US, UK, Israel and India. QualiTest focuses on large global enterprises in the technology, telecom, healthcare, finance, defense, media, utilities and retail industries and offers a wide range of testing solutions to meet customers' business requirements. QualiTest designs and delivers solutions that leverage deep industry-specific understanding with cutting-edge, testing technology and expertise. QualiTest delivers results by combining customer-centric business models, critical thinking and the ability to gain a profound comprehension of partners' goals and challenges.
News Article | November 22, 2016
Note to Editors: There is a photo associated with this press release. The Global 7000 first flight test vehicle has successfully transferred to the Bombardier Flight Testing Center in Wichita ahead of schedule. The program's flight validation is progressing well with five additional flights completed since the historic first flight on November 4, 2016. Bombardier is the world's leading manufacturer of both planes and trains. Looking far ahead while delivering today, Bombardier is evolving mobility worldwide by answering the call for more efficient, sustainable and enjoyable transportation everywhere. Our vehicles, services and, most of all, our employees are what make us a global leader in transportation. Bombardier is headquartered in Montréal, Canada. Our shares are traded on the Toronto Stock Exchange (BBD) and we are listed on the Dow Jones Sustainability World and North America Indices. In the fiscal year ended December 31, 2015, we posted revenues of $18.2 billion. News and information are available at bombardier.com or follow us on Twitter @Bombardier. Follow @Bombardierjets on Twitter to receive the latest news and updates from Bombardier Business Aircraft. To receive our press releases, please visit the RSS Feed section. Bombardier, Global 7000 and The Evolution of Mobility are trademarks of Bombardier Inc. or its subsidiaries. To view the photo associated with this press release, please visit the following link: http://media3.marketwire.com/docs/global7000.jpg.